Argenx Unveils Major New Clinical Data on VYVGART at AAN 2026
Argenx announces through a press release that it will present new clinical data at the American Academy of Neurology (AAN) annual conference in April 2026, focusing on its VYVGART treatments and development phase candidates in the field of autoimmune diseases.
During the AAN conference in Chicago (April 18-22, 2026), the immunology group will display clinical results for VYVGART (available in intravenous and subcutaneous Hytrulo formulations) as well as for its drug candidates empasiprubart and adimanebart. Argenx indicates that the data presented will include Phase 3 results in ocular myasthenia gravis, data supporting the use of VYVGART in patients with generalized myasthenia gravis without detectable anti-acetylcholine receptor antibodies, and in adolescents. The group also plans to present analyses on the long-term safety and efficacy of VYVGART in clinical and real-life settings, as well as data on the candidate adimanebart in congenital myasthenic syndromes.
Advancing the Pipeline with New Mechanisms of Action
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Argenx continues to advance its pipeline with two new mechanisms of action, aiming to develop precision therapies for multiple neurological diseases. In the field of chronic inflammatory demyelinating polyneuropathy (CIDP), the company will highlight results from post hoc analyses and data from the neurofilament light chain biomarker. For the candidate adimanebart, Argenx plans to share results from a Phase 1b trial in patients with congenital myasthenic syndromes linked to a DOK7 variation, accompanied by a proof of concept demonstration. The group emphasizes its commitment to expanding access to targeted treatment options for as many myasthenia gravis patients as possible.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 4 605 millions de dollars
Quarterly revenue: 4 605 millions de dollars
Revenue growth: 57,4 %
Net income: 1 344 millions de dollars
Guidance from the release
argenx remains on track to achieve its 'Vision 2030' anchored in the ambition to treat 50,000 patients globally
Risks mentioned
The risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials
Demand and commercialization risks for argenx's products and product candidates, including new indications
Regulatory and pricing uncertainties for argenx's products and product candidates if approved
Opportunities identified
Vision 2030 targets: treat 50,000 patients globally, secure 10 labeled indications, and progress five pipeline candidates
Multiple label and indication expansions for VYVGART being pursued across additional autoimmune diseases
Next-generation FcRn molecules (ARGX-213 Phase 3-ready, ARGX-124 in Phase 1) advancing through development
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
